Flavone acetic acid (FAA, NSC 347512) is a new antitumour compound under early clinical investigation in Europe and USA. Considerable interest in this drug derives from preclinical observations that, in contrast to most available anticancer agents, FAA is more effective on slow growing solid tumours (e.g., mouse colon 38 adenocarcinoma) than on rapidly proliferating leukemias (e.g., L1210, P388) (Corbett et al., 1986; Bibby et al., 1987; ). In addition FAA shows no bone marrow toxicity which is the most frequent drawback of antineoplastic drugs (Kerr et al., 1986; Zaharko et al., 1986) .
Although the effectiveness of FAA has been studied extensively on a broad spectrum of murine tumours, little information is available on the activity of the drug against human tumours transplanted in immunosuppressed or athymic (T-cell deficient) nude mice. To our knowledge, only preliminary findings are available showing that a recently established human melanoma was responsive to FAA, while two other xenografts, human mammary and human colon carcinomas evaluated in the subrenal capsule assay, did not respond (NCI Clinical Brochure, 1985) .
To obtain more information on the potential efficacy of FAA against human colorectal carcinoma (HCC), we examined its activity against two recently established HCC transplanted into nude mice (Giavazzi et al., 1986b) . The recent characterization of an experimental nude mouse model to study the production of liver tumours by HCC made it possible to explore the activity of this new drug against the formation of liver tumour colonies also (Giavazzi et al., 1986a supplemented with 10% foetal calf serum (Gibco Europe, Glasgow, Scotland), 5 ng ml-epidermal growth factor, 5 ,ug ml'-insulin, and 2 pg ml-1 transferrin (Sigma, St.
Louis, MO). Experiments were made with the cell line within 20-30 passages from its initial culture, Single cell suspensions were obtained by harvesting the monolayer with 0.125% trypsin-0.02% EDTA in phosphate buffer saline without Ca + + and Mg tt . After washes tumour cells were resuspended in Ca' t and Mgt'-free Hanks' balanced salt solution' (HBSS) and 2 x 106 cells in a volume of 0.2 ml HBSS were injected in the flank of nude mice. At this cell concentration all the mice produced a palpable tumour within 15-20 days from tumour cell injection. HCC-P2988 is a slow-growing tumour in the nude mouse with a s.c. doubling time of 11 + 2.4 days. It is not spontaneously metastatic in the nude mouse and does not produce liver colonies after intrasplenic (i.s.) injection.
HCC-M1410 was obtained from a hepatic metastasis of a patient with a primary rectal tumour (Giavazzi et al., 1986b) . The surgical specimen, dissociated by enzymatic digestion, was transplanted and maintained in nude mice by i.m. passage of 1 x 106 single cell suspension. Experiments were performed between passages 6-10 from the xenograft of the surgical specimen. A single cell suspension of the HCC-M1410 growing i.m. was obtained as described previously in detail (Giavazzi et al., 1986b) . Briefly, tumours from a group of 5 mice were cut into fragments and exposed to 20 min sequential dissociations with collagenase type I (200 U ml-) and DNase (270 U ml-1) (Sigma) at 37°C. The cell suspension was filtered through gauze and 100pm nylon mesh and washed repeatedly. Five x 105 and 1 x 106 viable tumour cells, by trypan blue exclusion, in 0.1 ml HBSS were injected s.c. or i.s. in the nude mouse, as specified in Results. After s.c. injection of these cell concentrations all mice developed a palpable tumour within 15 and 10 days respectively, with a doubling time of 4.5 + 1.1 days. After i.s. injection mice developed liver colonies and died because of the liver tumour burden respectively 5 and 4 weeks after tumour cell injection (Giavazzi et al., 1986a injection over a period of 1 min.
Subcutaneous tumour assay
Therapy was begun when all mice had a palpable tumour growing s.c. In one experiment, treatment started 3 days after HCC-M1410 cell injection. Mice were randomized to various treatment and control groups. The diameters of tumours growing s.c. were measured in cm twice a week by caliper and tumour weight in g was estimated by the formula, length x width2/2. Mean tumour weights were plotted against days after tumour cell injection. Percentage of tumour inhibition on the day indicated was calculated as 100 -[(median tumour weight of treated mice/median tumour weight of control mice) x 100].
Liver tumour assay
The production of tumour colonies in the livers of nude mice was examined after i.s. injection of HCC-M 1410 cells as described previously (Giavazzi et al., 1986a) . Briefly, in anaesthetized nude mice an incision was made in the left flank, carried down through the peritoneal wall and the spleen was exposed. Cell suspensions in 0.1ml HBSS were injected into the spleen. Visible 'paling' of the spleen and lack of bleeding were the criteria for a successful inoculation. The spleen was then returned into the peritoneal cavity and the abdominal wall was closed with sutures and the skin with wound clips.
Autopsies were performed 30 days after tumour cell injection. The liver and the spleen were removed and weighed. Livers were fixed in Bouin's solution and the number of colonies was counted under a dissecting microscope. Organs with no visible tumour were fixed in 10% buffered formalin and processed for histological examination.
Statistical analysis Differences in the numbers of liver colonies, and in tumour weights and survival times were analyzed by the MannWhitney U test.
Results
Effect of FAA on primary HCC-P2988 The activity of FAA against the s.c. grafted HCC-P2988 is shown in Figure 1 and Table I . Treatment was started when all mice had a palpable, progressively growing tumour. Injections of 200 mg kg-I FAA every 4 days (Q4d x 3) significantly slowed tumour growth (Figure 1 ). This was followed by an increase in survival time for treated mice (median = 160 days) compared to control mice (median = 127 days). A dose of 100 mg kg-1 daily (Qld x 6) or 240 mg kg-I weekly (Q7d x 2) had no effect on tumour growth (Table I) (Figure 2a) . Treatment of the HCC-M1410, transplanted s.c., as early as 3 days after injection delayed tumour appearance (Figure 2b ) but this was not followed by any significant difference in survival time and none of the mice were tumour free 30 days after tumour cell injection (data not shown). After i.s. injection, HCC-M1410 cells grew in the liver and mice died with the liver parenchyma replaced by tumour (Figure 3) . Figure 4 shows that three days after i. 
Discussion
In this study we found that FAA had moderate activity against the slow-growing HCC-P2988 transplanted s.c. into nude mice. HCC-M1410 growing s.c. in nude mice was almost unresponsive but growing in the liver of nude mice responded significantly. HCC-M1410 is a highly malignant tumour that consistently produces tumour colonies in the liver of nude mice after i.s. injection (Giavazzi et al., 1986a, b) . Treatment with FAA significantly reduced the liver tumour burden (Figure 3) . FAA treatment was started three days after i.s. tumour cell injection, by which time single neoplastic cells and/or small tumour emboli are already present in the liver and capillary bed. A low tumour burden certainly accounts for the observed response of HCC-M1410 in the liver. However, FAA treatment starting three days after s.c. injection of HCC-M 1410 cells only delayed tumour appearance, with no effect on the rate of tumour growth.
The formation of metastases in a patient with colorectal tumour represents a major problem in clinical oncology. About 50% of malignant HCC have already metastasized at the time of diagnosis, mainly to lymph nodes and liver, and many more have undetectable micrometastases (August et al., 1984 (Giavazzi et al., 1986a) . We have also seen that radiolabeled tumour cells reached the liver of nude mice within a few minutes of injection into the spleen (Giavazzi et al., 1986a) .
Neoplasms can be heterogeneous for many aspects including drug sensitivity. Differences between primary tumour and metastases have also been described (Siracky, 1979; Slack & Bross, 1975; Tsuro & Fidler, 1981; Trope, 1975; Von Hoff et al., 1986 (Abe et al., 1985; Donelli et al., 1977; Selby et al., 1979) . In this respect it may be worth recalling that in nude mice the highest concentrations of FAA were found in the liver (Damia et al., 1987) , suggesting that the better effect against liver tumour colonies may be due to favourable drug distribution. Furthermore the doubling time of tumour cells in a small population (liver micrometastases) is often shorter than in a larger population (s.c. growing tumour), and therefore micrometastases should be more sensitive to anticancer drugs than larger primary tumours (Schabel, 1975) . We have to consider, however, that FAA, in contrast to most other antitumour agents, does not cause detectable perturbation in the cell cycle (Capalongo et al., 1987) and is very effective against slow-growing mouse tumours. Therefore it is unlikely that the preferential activity of FAA against small liver tumour deposits compared to a s.c. growing tumour is due to kinetic factors.
Recently it was suggested that FAA antitumour activity is mediated through the activation of natural killer (NK) cells (Ching & Baguley, 1987; Wiltrout, 1987) . Injection of FAA i.v. augmented NK activity in the lung, and especially in the spleen and liver of mice (Wiltrout, 1987) . NK cells have been described as playing an important role in control of the metastatic spread of tumour cells. Low NK activity in rodents has been associated with an increase in experimental metastasis formation in the lung (Barlozzari et al., 1985; Hanna, 1982) . We have found that i.s. injection of HCC cells in anti-asialo GM1 serum pretreated nude mice (low NK activity) led to a significant increase of liver tumour foci (unpublished data). The possibility that the antineoplastic effect of FAA observed in the spleen and liver of nude mice results mainly from an immunomodulatory activity rather than any direct antitumour activity remains for the moment mere speculation.
The present findings show that FAA can be active on HCC grafted in nude mice. Its preferential activity against liver tumour formation makes this new agent potentially useful in the therapy of micrometastases.
